SCHEMBL26663232

SCHEMBL26663232

CC(C)(C)OC(=O)N1C(=O)CC2CC1C2

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.47
CHRM1 P11229 1/20 0.47
CHRM3 P20309 1/20 0.47
NR1H2 P55055 1/20 0.37
EPHX2 P34913 1/20 0.36
KDM4E B2RXH2 2/20 0.36
HSD11B1 P28845 1/20 0.36
USP2 O75604 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PREP P48147 2/20 0.35
MAPT P10636 1/20 0.35
THRB P10828 1/20 0.35
HPGD P15428 1/20 0.33
KLK7 P49862 1/20 0.33
KLK5 Q9Y337 1/20 0.33
AR P10275 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3385088 0.79 CHRM2 (0.42) CHRM2CHRM1CHRM3NR1H2KDM4E
SCHEMBL20406585 0.77 CHRM2 (0.43) CHRM2CHRM1CHRM3NR1H2KDM4E
SCHEMBL483259 0.77 CHRM2 (0.43) CHRM2CHRM1CHRM3NR1H2KDM4E
SCHEMBL30918715 0.76 CHRM2 (0.44) CHRM2CHRM1CHRM3NR1H2KDM4E
SCHEMBL20929429 0.76 CHRM2 (0.44) CHRM2CHRM1CHRM3NR1H2KDM4E
SCHEMBL30918718 0.76 CHRM2 (0.44) CHRM2CHRM1CHRM3NR1H2KDM4E
SCHEMBL539900 0.76 CHRM2 (0.44) CHRM2CHRM1CHRM3NR1H2KDM4E
SCHEMBL19420020 0.75 CHRM2 (0.46) CHRM2CHRM1CHRM3NR1H2KDM4E
SCHEMBL22096750 0.75 CHRM2 (0.46) CHRM2CHRM1CHRM3NR1H2KDM4E
SCHEMBL15018313 0.75 CHRM2 (0.42) CHRM2CHRM1CHRM3NR1H2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346602-A1 LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF DICE ALPHA INC (US) 2025-11-13 US disclosed
EP-4525987-A1 LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF Dice Alpha, Inc. (US) 2025-03-26 EP disclosed
CN-119677749-A Azaquinazoline pan KRAS inhibitors 米拉蒂治疗股份有限公司 2025-03-21 CN disclosed
WO-2023225664-A1 LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. (US) 2023-11-23 WO disclosed
WO-2023225664-A1 LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. (US) 2023-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346602-A1 LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF IL17A, IL15, IL18 CHRM2 4776/4885CHRM1 4592/4885CHRM3 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.